Premium
Effect of colestilan on serum phosphorus in dialysis patients: A meta‐analysis of the literature
Author(s) -
Zhang Qian,
Li Ming,
Chen Jing
Publication year - 2016
Publication title -
nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 61
eISSN - 1440-1797
pISSN - 1320-5358
DOI - 10.1111/nep.12588
Subject(s) - medicine , meta analysis , phosphorus , dialysis , intensive care medicine , metallurgy , materials science
Aim To evaluate the efficacy and safety of colestilan as a phosphorus binder in dialysis patients, we performed a meta‐analysis of randomized controlled trials. Methods We retrieved studies that compared colestilan with placebo in the treatment of dialysis patients from Medline, EMBASE , the C ochrane L ibrary and conference proceedings. Results Four studies were included. The treatment durations ranged from 2 to 12 weeks, median 7.5 weeks. Compared with placebo group, colestilan significantly decreased serum phosphorus ( WMD , −0.22 mmol/L; 95% CI , −0.33 to −0.12, P < 0.0001), calcium phosphorus product ( WMD , −0.70 mmol 2 /L 2 ; 95% CI , −1.06 to −0.35, P = 0.0001), intact PTH ( WMD , −5.37 pmol/L; 95% CI , −8.38 to −2.36, P = 0.0005) and LDL cholesterol ( WMD , −0.78 mmol/L; 95% CI , −0.85 to −0.71, P < 0.00001). There was no significant difference in serum calcium between the two groups. Colestilan therapy increased gastrointestinal complaints significantly ( OR = 4.07, 95% CI : 3.06–6.53, P < 0.00001). Sensitivity analysis was performed by excluding studies with Jadad score of three or 3 g/day colestilan, the results did not change. Conclusions Short‐term administration of colestilan is effective for the treatment of hyperphosphataemia in dialysis patients. Long‐term effectiveness and safety needs to be evaluated.